Safety and efficacy of linezolid in 16 infants and children in Japan

Masayoshi Shinjoh, Osamu Iketani, Kota Watanabe, Naoki Shimojima, Mikihiko Kudo, Hiroyuki Yamagishi, Hiroyuki Shimada, Kayoko Sugita, Takao Takahashi, Takehiko Mori, Naoki Hasegawa, Satoshi Iwata

研究成果: Article査読

6 被引用数 (Scopus)


Linezolid, an oxazolidinone antibiotic, exhibits a broad spectrum of activity against Gram-positive bacteria. It hasbeen licensed for adult use in Japan since 2006 for MRSA infections, and has also been used off-label for pediatric patients.At our university hospital, a total of 16 infants and children (including one non-Japanese Asian) were administered linezolidowing to infection with multidrug-resistant Gram-positive bacteria, after consent had been provided. All patients had severeunderlying diseases or indications for surgery. Eighty-eight percent of the causal microorganisms were methicillin-resistantStaphylococcus aureus (MRSA) or methicillin-resistant coagulase-negative Staphylococcus and all were sensitive to linezolid.Linezolid was administered because the antecedent anti-MRSA medications were ineffective or contraindicated, orintravenous-to-oral switch therapy was requested owing to cardiac or orthopedic surgical-site infections. The median durationof administration was 13 days (range 3-31 days). The overall efficacy was 91 % (10/11) in those for whom efficacy could beevaluated. Only two patients (both teen-aged) encountered linezolid-related adverse effects (13 %, 2/16). One patient showedelevation of liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]), requiring thatadministration be withdrawn, but enzyme levels returned to normal after the patient had been switched to vancomycin. Theother patient showed transiently decreased platelet counts. Linezolid is considered generally safe and effective for childrenin Japan, especially for those who cannot use other anti-MRSA medications or those who require oral antibiotics forinfections with multidrug-resistant Gram-positive bacteria.

ジャーナルJournal of Infection and Chemotherapy
出版ステータスPublished - 2012 8月

ASJC Scopus subject areas

  • 微生物学(医療)
  • 薬理学(医学)
  • 感染症


「Safety and efficacy of linezolid in 16 infants and children in Japan」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。